Twist Bioscience Corporation Proceeds from Common Stock Issued
Twist Bioscience Corporation (TWST) reported Proceeds from Common Stock Issued of $107.50 million for the 9-month period ending 2020-06-30, per its 10-Q filed 2020-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2020-08-12
- 2020-06-30: Proceeds from Issuance of Common Stock 9 month $107.50M.
- 2019-05-31: Proceeds from Issuance of Common Stock 1 month $84.30M.
- 2018-10-31: Proceeds from Issuance of Common Stock 1 month $69.60M.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 9 month |
|---|---|---|
| 2020-06-30 | $107.50M 10-Q · filed 2020-08-12 | |
| 2019-05-31 | $84.30M 10-K · filed 2019-12-13 | |
| 2018-10-31 | $69.60M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |